BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 32360510)

  • 1. Single-Cell Transcriptome in Chronic Myeloid Leukemia: Pseudotime Analysis Reveals Evidence of Embryonic and Transitional Stem Cell States.
    Pagliaro S; Desterke C; Acloque H; Chomel JC; de Souza L; Hugues P; Griscelli F; Foudi A; Bennaceur-Griscelli A; Turhan AG
    Exp Hematol; 2020 May; 85():47-56.e2. PubMed ID: 32360510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
    Čokić VP; Mojsilović S; Jauković A; Kraguljac-Kurtović N; Mojsilović S; Šefer D; Mitrović Ajtić O; Milošević V; Bogdanović A; Đikić D; Milenković P; Puri RK
    Blood Cells Mol Dis; 2015 Dec; 55(4):373-81. PubMed ID: 26460262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
    Diaz-Blanco E; Bruns I; Neumann F; Fischer JC; Graef T; Rosskopf M; Brors B; Pechtel S; Bork S; Koch A; Baer A; Rohr UP; Kobbe G; von Haeseler A; Gattermann N; Haas R; Kronenwett R
    Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
    Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
    PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia.
    Chen Y; Sullivan C; Peng C; Shan Y; Hu Y; Li D; Li S
    Blood; 2011 Jul; 118(2):390-400. PubMed ID: 21596859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MIP-1α/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice.
    Baba T; Tanabe Y; Yoshikawa S; Yamanishi Y; Morishita S; Komatsu N; Karasuyama H; Hirao A; Mukaida N
    Blood; 2016 May; 127(21):2607-17. PubMed ID: 27006388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34
    Dolinska M; Piccini A; Wong WM; Gelali E; Johansson AS; Klang J; Xiao P; Yektaei-Karin E; Strömberg UO; Mustjoki S; Stenke L; Ekblom M; Qian H
    Biochem Biophys Res Commun; 2017 Aug; 490(2):378-384. PubMed ID: 28623130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.
    Biernacki MA; Marina O; Zhang W; Liu F; Bruns I; Cai A; Neuberg D; Canning CM; Alyea EP; Soiffer RJ; Brusic V; Ritz J; Wu CJ
    Cancer Res; 2010 Feb; 70(3):906-15. PubMed ID: 20103624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
    Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
    Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
    Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
    Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
    Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
    Moreno-Lorenzana D; Avilés-Vazquez S; Sandoval Esquivel MA; Alvarado-Moreno A; Ortiz-Navarrete V; Torres-Martínez H; Ayala-Sánchez M; Mayani H; Chavez-Gonzalez A
    Cell Cycle; 2016 May; 15(9):1276-87. PubMed ID: 26985855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelogenous leukemia molecular signature.
    Nowicki MO; Pawlowski P; Fischer T; Hess G; Pawlowski T; Skorski T
    Oncogene; 2003 Jun; 22(25):3952-63. PubMed ID: 12813469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
    Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
    Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells.
    Babashah S; Sadeghizadeh M; Hajifathali A; Tavirani MR; Zomorod MS; Ghadiani M; Soleimani M
    Int J Cancer; 2013 Aug; 133(3):579-89. PubMed ID: 23341351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.